Teva Pharmaceutical Industries Limited Earnings Recaps
Q3 2026
Nov 5, 2026
Teva shares rose 3.0% after earnings, with investors responding to growth in the innovative portfolio and higher margins despite a 2% decline in revenue. Generics weakness—largely tied to lower generic REVLIMID contribution—remains a counterweight.
Key takeaways
- Revenue was $4.4 billion, down 2% year over year; gross margin increased 345 basis points to 58.7%.
- EBITDA grew 7% and non-GAAP EPS rose 10%.
- Innovative portfolio revenue increased 32%; AUSTEDO sales were $751 million (+21%), UZEDY $85 million (+96%), and AJOVY $269 million (+61%).
- Generics revenue declined 16%, largely due to a lower contribution from generic REVLIMID.
- Teva said it discontinued the phase II emrusolmin study after an interim futility analysis; management reported no safety concerns.
Q3 2025
Nov 6, 2025
Teva Pharmaceutical Industries reported robust growth in Q3 2025, achieving its 11th consecutive quarter of revenue increase, with total revenue up 3% year-over-year and adjusted EBITDA rising 6%.
Key takeaways
- Revenue reached $4.5 billion, driven by a 33% increase in innovative product sales, totaling over $800 million.
- AUSTEDO's revenue grew 38% year-over-year, surpassing $600 million for the first time, and reaffirmed a 2027 revenue target of $2.5 billion.
- UZEDY experienced a 24% revenue increase with a 119% rise in TRx, confirming long-term peak sales ambitions of $1.5 billion to $2 billion.
- Free cash flow exceeded $0.5 billion, and net debt to EBITDA improved to below 3x, marking a significant financial milestone for the firm.
Q2 2025
Jul 30, 2025
Teva Pharmaceutical Industries reported solid Q2 2025 results, marking its 10th consecutive quarter of growth driven by strong performance in its innovative product portfolio, while overall revenues reached $4.2 billion, up 1%.
Key takeaways
- Adjusted EBITDA increased by 7%, and non-GAAP EPS rose 10%.
- Significant growth in innovative drugs: AUSTEDO up 19% to nearly $500 million, UZEDY up 120% to $54 million, and AJOVY up 31% to $155 million.
- The global generics business saw a decline of 2% amid strong prior year comparisons.
- Teva remains on track with its cost transformation programs, expecting to achieve mid-single-digit growth targets for 2027.